Galectin Therapeutics (GALT) develops carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the company’s unique approach of galectin proteins, key mediators of biologic function. Galectin announced today that it has received a notice of issuance from the U.S. Patent and Trademark Office for Patent Number 8,236,780. The patent covers key […]